Fulminant Cases Among Severe Community-acquired Pneumonia - an Observational Retrospective Study

What this Trial Is About

Severe community-acquired pneumonia (CAP) is a major cause of hospital deaths, especially when it progresses rapidly into a condition known as fulminant pneumonia. This rapid worsening can lead to severe acute respiratory distress syndrome (ARDS), acute respiratory failure, and septic shock within hours or days. The true frequency and best treatment approach for fulminant pneumonia remain unclear, partly because pneumonia is often studied separately from related conditions like ARDS and sepsis. The COVID-19 pandemic has highlighted the presence of fulminant pneumonias, increasing the need to understand this condition better. This observational study gathers data from patients hospitalized with severe CAP at five centers between January 2018 and July 2024. Patients included both COVID and non-COVID cases who met specific criteria for severe pneumonia and respiratory distress. Early antibiotic treatment was standard, while corticosteroid use depended on physician decisions or other protocols. The study excluded hospital- or healthcare-acquired pneumonia and patients with advanced chronic illnesses. Participants' clinical information was collected at admission, including oxygen levels, vital signs, age, ICU admission, hospital stay length, and ventilation details. Researchers will analyze mortality rates at 2, 7, 30, and 60 days to assess outcomes. The study seeks to better understand fulminant pneumonia rates and the role of early corticosteroid treatment in severe CAP patients. The total observation period spans from patient admission through at least 60 days for outcome assessment.

Fulminant Severe CAP - an Observational Study